114 results about "Dyslipidemia" patented technology

The invention discloses a polypeptide or a pharmaceutically acceptable salt thereof. The polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or an amino acid sequence in a conservative modification form thereof. The polypeptide or the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP1R and is used for effectively activating the GLP1R. The GLP1R activating polypeptide is obtained through precise calculation and deep learning model optimization, has a short sequence, has unique amino acid arrangement compared with a traditional GLP-1 analogue, can effectively activate a GLP1R receptor, can also be used for treating or preventing metabolic disorder related diseases, and has a good application prospect. For example, obesity, diabetes, dyslipidemia related diseases, fatty liver diseases, metabolic syndromes, non-alcoholic fatty liver diseases and the like.

The present disclosure relates to RNAi agents, e.g., double-stranded RNAi agents, e.g., siRNAs, capable of inhibiting expression of the subunit beta E (INHBE) gene. Also disclosed are pharmaceutical compositions comprising the INHBE RNAi agents, and methods of use thereof. The INHBE RNAi agents disclosed herein can be conjugated to targeting ligands to facilitate delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agent in vivo results in inhibition of expression of the INHBE gene. RNAi agents may be used in methods of treating diseases, disorders, or conditions mediated in part by the expression of the INHBE gene, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic diseases.

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and / or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and / or chronic weight management, dyslipidemia and / or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity, and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

To provide a novel material or composition that is effective in preventing or alleviating dyslipidemia. [Solution] A material or composition containing live or dead yeast cells or yeast hydrolysates for preventing or alleviating dyslipidemia. Dyslipidemia here refers to one or more abnormalities in blood concentrations of LDL cholesterol (bad cholesterol), HDL cholesterol (good cholesterol), and triglycerides (neutral fats). Zygosaccharomyces rouxii or Pichia are preferred as the yeast. The yeast is preferably of food origin and preferably intended for human consumption.

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of a subject suffering from or at an increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for treating a subject suffering from or having an increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The present disclosure relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the HMGCR receptor (expressed by the HMGCR gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases and disorders involving the regulation of HMGCR expression and function, such as diseases and disorders that are risk factors for ASCVD (such as, dyslipidemia, such as hypercholesteremia).

Disclosed herein are compounds suitable for use in the treatment of disorders, e.g., diabetic disorder, a dyslipidemia disorder, a cardiovascular disorder, an inflammatory disorder, a hepatic disorder, cancer, or obesity or co-morbidities thereof. Also disclosed are compositions containing one or more of the compounds and uses of the compounds in the treatment of disorders in a subject.

The invention discloses a traditional Chinese medicine composition for treating gallstone and a preparation method thereof, and relates to the technical field of traditional Chinese medicine compositions, and the traditional Chinese medicine composition for treating gallstone is characterized by comprising the following components: lysimachia christinae hance, endothelium corneum gigeriae galli, lygodium japonicum, radix curcumae, corn stigma and szechwan chinaberry fruit. Clinical and experiments prove that the traditional Chinese medicine composition can effectively eliminate clinical symptoms of gallstone, and can correct liver function and dyslipidemia, relieve the inflammation level, regulate abnormal metabolism of cholesterol-bile acid, remarkably promote dissolution and discharge of gallstone and inhibit recurrence of gallstone. The traditional Chinese medicine composition not only can effectively prevent and treat gallstone and remarkably relieve clinical symptoms of patients, but also can reduce the treatment cost and avoid pain caused by operations, and has a wide application prospect.

The present invention relates to a composition comprising a complex extract of Coptis japonica, Phellodendron Chinensis, Scutellaria baicalensis, Gardenia jasminoides, and Rheum palmatum. The composition was confirmed to: reduce the levels of blood cholesterol, blood lipids, and blood LDL-cholesterol in patients with dyslipidemia; reduce systolic blood pressure without affecting diastolic blood pressure and pulse rate in patients with hypertension; reduce the level of pulse wave velocity (PWV), which is an indicator of arteriosclerosis, in patients with atherosclerosis, and inhibit the recurrence rate for up to 5 years in patients with cerebral infarction. Accordingly, the composition is provided as a therapeutic agent for dyslipidemia, hypertension, arteriosclerosis, or cerebral infarction. In particular, the composition is made into an encapsulated form rather than conventional decoctions, to reduce the content of geniposide, which is reported as a side effect component, and thus an optimal composition which maintains efficacy against dyslipidemia and does not cause side effects is provided.

The invention discloses a traditional Chinese medicine composition for treating and preventing cardiovascular and cerebrovascular diseases and postoperative repair and recuperation based on classic famous prescription, and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition is prepared by combining a prescription based on coptis and colla corii asini decoction, cassia twig decoction, cinnamomum cassia and aconitum carmichaeli decoction and poria cocos, cinnamomum cassia and aconitum carmichaeli decoction, as well as poria cocos, cinnamomum cassia and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction and poria cocos and In the formula, ligusticum wallichii and earthworm promote blood circulation to remove blood stasis, dredge collaterals and dissolve thrombus; hawthorn and lotus leaf are used for dissolving turbidity, lowering lipid and regulating blood fat and cholesterol; the poria cocos and the rhizoma alismatis are used for clearing damp and promoting diuresis. The whole formula has the effects of warming yang, dredging collaterals, nourishing yin and blood, promoting blood circulation to remove blood stasis, dissolving turbidity, reducing lipid, calming the heart, soothing the nerves and the like, can be used for treating cardiovascular and cerebrovascular diseases, conditioning dyslipidemia, preventing atherosclerosis and postoperative repair and nursing at the same time, is wide in application range and high in safety, can be prepared into various oral dosage forms, and has a good application prospect.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

Aspects of the disclosure relate to compositions and methods for multiplexed gene silencing in a cell or subject. In some embodiments, the disclosure provides an isolated nucleic acid or an rAAV encoding a transgene comprising a RNA-guided nuclease (RGN) operably linked to a first promoter, and a second promoter operably linked to a multi guide-RNA (multi-gRNA) expression cassette encoding one or more gRNAs targeting a gene associated with hypercholesterolemia or dyslipidemia. In some embodiments, the disclosure provides methods of treating a subject having hypercholesterolemia or dyslipidemia by administering the compositions.

The invention provides a small molecule compound A5 with a good treatment effect on metabolism-related fatty liver diseases, a novel pyrene derivative A5 is successfully prepared through an organic synthesis approach, and the novel pyrene derivative A5 is proved to have a definite treatment effect on the metabolism-related fatty liver diseases on the basis of in-vivo and in-vitro pharmacodynamic experiments. The invention further provides an application of the hydroxypyrene derivative A5 in preparation of drugs for preventing and / or treating metabolism-related fatty liver diseases. The compound can remarkably improve characteristic pathological changes of the metabolism-related fatty liver disease, including regulation of dyslipidemia, inhibition of hepatocyte vacuolar degeneration and delay of liver fibrosis progress, shows the advantage of multi-target treatment, and shows a remarkable curative effect in treatment of the metabolism-related fatty liver disease.

Provided are a compound represented by a Formula (1) or a salt thereof, and a method for producing the compound represented by the Formula (1). In the formula, two R1 symbols each independently represent a hydrogen atom or an alkyl group. Two instances of the letter n each independently represent an integer of 0 or more. R3, R4, and R5 symbols each independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, or the like. In addition, the present invention provides a prophylactic or therapeutic agent for dyslipidemia or dyslipidemia-related diseases, the agent including, as an active ingredient, a compound represented by Formula (1) or a salt thereof.

Provided is a pharmaceutical composition comprising pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity.SOLUTION: A pharmaceutical composition comprising the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; (B) the following component (B-2); and (B-2) a starch, wherein the pharmaceutical composition is a solid preparation. However, the following (1) and (2) are excluded. (1) A pharmaceutical composition for preventing and / or treating dyslipidemia, comprising pemafibrate, a salt thereof or a solvate of any of these and a cholesterol absorption inhibitor, wherein pemafibrate, a salt thereof or a solvate of any of these and the cholesterol absorption inhibitor are formulated into a single preparation. (2) A pharmaceutical composition for preventing and / or treating dyslipidemia for use in a kit together with a pharmaceutical composition for preventing and / or treating dyslipidemia comprising a cholesterol absorption inhibitor, the pharmaceutical composition comprising pemafibrate, a salt thereof or a solvate thereof.SELECTED DRAWING: None

A polyhydroxyalkanoate (PHA) containing monomer units of 3-hydroxybutyrate for use, by oral administration, in the prevention or treatment of an overweight or obesity condition, or of metabolic dysfunctions related to the condition. A marked effect was observed on the reduction of the body weight, both in the case of a standard diet and in the case of a diet rich in fats, a reduction that can be attributed to an increase in lipid oxidation to the detriment of the deposit of excess lipids, as confirmed by the decrease in the body weight and by analyses of the body composition. A positive effect on the metabolic dysfunctions related to an overweight or obesity condition has also been verified, in particular on dyslipidemias, such as the blood level of low-density lipoproteins (LDL cholesterol) and triglycerides, as well as an improvement in the inflammatory state.

The invention discloses compound safflower tea capable of reducing blood lipid. The compound safflower tea consists of the following components: 0.19 to 0.21 g of safflower, 0.195 to 2.050 g of American ginseng, 0.90 to 1.10 g of green tea, 1.10 to 1.20 g of hawthorn and 1.35 to 1.45 g of lotus leaf. According to the present invention, the C57BL / 6J mouse is subjected to the lipid-lowering experiment by using the safflower as the main material and using the American ginseng, the green tea, the hawthorn and the lotus leaf as the auxiliary materials, and the result shows that the safflower lipid-lowering tea can significantly reduce the levels of serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C), can improve the liver fatty degeneration and the inflammatory reaction, and can alleviate the intestinal injury caused by the high fat diet; animal behavior experiments including Y maze, open field experiments and new object recognition experiments are used to verify that the safflower lipid-lowering tea has an improvement effect on mouse cognitive impairment caused by dyslipidemia.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia, FCS, LPLD, in a patient. Further provided herein are methods, compounds, and compositions for increasing HDL levels and / or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof.

Oligonucleotides and compositions including the same are disclosed that modulate (e.g., inhibit, limit or reduce) sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) activity. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders, and / or conditions associated with SCAP activity such as nonalcoholic fatty liver disease (NAFLD), (NASH), dyslipidemia, atherosclerotic cardiovascular disease (ASCVD), and / or other SCAP-associated conditions, diseases, and / or disorders.

The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin / kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

The present invention relates to a dual-targeting siRNA agent comprising two distinct siRNAs targeting two different genes or their pharmaceutically acceptable salts, wherein the two distinct siRNAs or their salts are linked by a pharmaceutically acceptable ligand. The siRNA is a dsRNA composed of a sense strand and an antisense strand, and the two different genes are selected from a group consisting of angiotensinogen (AGT), proprotein convertase subtilisin / kexin type 9 (PCSK9), and human angiopoietin-like protein 3 (ANGPTL3). The present invention provides the application of the dual-targeting siRNA agent in the preparation of drugs for preventing or treating diseases associated with hypertension and / or dyslipidemia. The dual-targeting siRNA agent described in the present invention can effectively inhibit the expression of two target genes simultaneously in vivo, offering the advantages of strong non-antagonistic activity and high safety. The present invention also provides the siRNAs targeting corresponding genes for the aforementioned dual-targeting siRNA agent and their use for preventing or treating diseases associated with hypertension and / or dyslipidemia.

Disclosed herein are compounds suitable for use in the treatment of disorders, e.g., diabetic disorder, a dyslipidemia disorder, a cardiovascular disorder, an inflammatory disorder, a hepatic disorder, cancer, or obesity or co-morbidities thereof. Also disclosed are compositions containing one or more of the compounds and uses of the compounds in the treatment of disorders in a subject.

The invention discloses a lipid-lowering weight-losing tanshinone IIA double-layer polymer soluble acupoint microneedle and a preparation method and application thereof.The microneedle is of a layered structure design, and a needle body of the microneedle is prepared from a tanshinone IIA ethanol-water solution, polyvinylpyrrolidone K30 and chondroitin sulfate; the substrate of the backing layer is prepared from a tanshinone IIA ethanol-water solution and polyvinyl alcohol. The insoluble drug tanshinone IIA is successfully loaded in the soluble microneedle through a specific ethanol-water co-solvent system and a micro-molding forming process, the microneedle array is complete in form, sharp in needle shape and excellent in mechanical strength, and can effectively puncture the skin cuticle, after puncturing, the needle body can be rapidly dissolved in the skin interstitial fluid, and therefore the skin cuticle can be effectively punctured. The efficient release of the medicine is realized; the irritation to the skin is avoided. The core innovation of the invention lies in that the modern microneedle transdermal drug delivery technology and the traditional Chinese medicine acupoint therapy are combined for application, so that the dyslipidemia condition caused by hyperlipidemia diet can be obviously regulated, and the effects of regulating body weight and reducing blood fat can be achieved.

Disclosed herein are compounds suitable for use in the treatment of disorders, e.g., diabetic disorder, a dyslipidemia disorder, a cardiovascular disorder, an inflammatory disorder, a hepatic disorder, cancer, or obesity or co-morbidities thereof. Also disclosed are compositions containing one or more of the compounds and uses of the compounds in the treatment of disorders in a subject.

The invention relates to the technical field of coreopsis tinctoria refined components and preparation and application, and provides a coreopsis tinctoria refined component and a preparation method and application thereof.The coreopsis tinctoria refined component comprises, by mass, 11 specific components of phenolic acids, flavonol, flavanol and flavonoid, and the 11 specific components comprise, by mass, 2 parts of gallic acid, 1 part of potassium sorbate, 1 part of potassium sorbate, 1 part of potassium sorbate and 1 part of potassium sorbate. The health-care food is prepared from the following raw materials in parts by weight: 3 parts of chlorogenic acid, 14 parts of quercetin, 18 parts of catechin, 5 parts of citric acid, 2-3 parts of procyanidine B, 3 parts of (+)-epicatechin, 1-31 parts of 31 parts of procyanidine C, 14 parts of rutin, 4 parts of camphanol-3-O-rutinoside and 2 parts of isorhamnetin-3-O-rutinoside. The snow chrysanthemum is Changbai Mountain snow chrysanthemum. Animal experiments show that the refined component can significantly reduce the content of total cholesterol and triglyceride in serum of a high-fat model rat, the specific component with blood fat regulating activity is prepared from Changbai Mountain snow chrysanthemum, and a new choice is provided for non-drug intervention of dyslipidemia.

Pharmaceutical compositions comprising a C1-C4 alkyl ester azelate, such as diethyl azelate (DEA), dimethyl azelate (DMA), di-isopropyl azelate (DiPA), di-isobutyl azelate (DiBuA), and di-2-pentyl azelate (D2PA), and methods of, inter alia, improving abnormal lipid levels and treating or preventing dyslipidemias and / or diseases of conditions associated therewith comprising administering to a subject such pharmaceutical compositions, are provided.